ARCH-affiliated entities report beneficial ownership filing for Lyell Immunopharma common stock. The cover rows show shared voting and dispositive power over 3,247,162 shares for multiple ARCH entities and individuals. The percentage figures are calculated using 23,334,087 shares outstanding as of May 1, 2026.
The filing lists record ownership positions: AVF IX and related AVP entities hold record shares of 910,317 each in certain funds, while AVF XIII shows 1,426,528 shares. Reporting Persons disclaim beneficial ownership except for shares held of record.
Positive
None.
Negative
None.
Insights
Large ARCH-related block appears as shared control of roughly 3.25M Lyell shares.
The cover rows indicate multiple ARCH funds and principals exercise shared voting and dispositive power over 3,247,162 shares, equal to 13.9% of the class using the issuer's reported 23,334,087 shares outstanding as of May 1, 2026. This is a concentrated ownership stake disclosed via Schedule 13G/A.
Dependency and risk: the positions are reported as shared control among funds and named individuals; the filing expressly includes disclaimers of individual beneficial ownership. Subsequent filings may clarify any transfers or changes in voting arrangements.
Filing shows governance linkage across ARCH entities and named directors/MDs.
The report associates AVF IX, AVF XIII, AVP entities, and named Managing Directors with shared authority to vote or dispose of the IX Record Shares and XIII Record Shares. Percentages reference the issuer's Form 10-Q count.
Material note: the report contains multiple interrelated entities and committee roles; readers should consult subsequent ownership filings for any changes to sole versus shared power or for transfers that would alter reported percentages.
Key Figures
Shares outstanding (used):23,334,087 sharesShared voting/dispositive power:3,247,162 sharesAVF IX record ownership:910,317 shares+4 more
7 metrics
Shares outstanding (used)23,334,087 sharesas of May 1, 2026 (per issuer Form 10-Q)
Shared voting/dispositive power3,247,162 sharesreported on cover rows as shared power
AVF IX record ownership910,317 sharesAVF IX record owner as of March 31, 2026
AVF XIII record ownership1,426,528 sharesAVF XIII record owner as of March 31, 2026
Reported percent of class13.9%percentage for 3,247,162 using 23,334,087 shares outstanding
Alternate reported position (Bybee)1,820,634 sharesshared voting/dispositive power listed for Clinton Bybee
Paul Berns position1,426,528 sharesshared voting/dispositive power listed for Paul Berns
Key Terms
Shared Dispositive Power, Beneficially owned, Record owner, CUSIP
4 terms
Shared Dispositive Powerregulatory
"row entries list "Shared Dispositive Power 3,247,162.00""
Beneficially ownedregulatory
"Item 4(a) states "Amount beneficially owned" and describes record ownership counts"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Record ownerregulatory
"Item 4(a) references "AVF IX is the record owner of 910,317 shares""
CUSIPtechnical
"Item 2(d) lists CUSIP No.: 55083R203"
A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Lyell Immunopharma, Inc.
(Name of Issuer)
Common Stock par value $0.0001 per share
(Title of Class of Securities)
55083R203
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Fund IX, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Fund IX Overage, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Fund XIII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Partners IX, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Partners IX Overage, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Partners IX, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Partners XIII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
ARCH Venture Partners XIII, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
Keith Crandell
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
Clinton Bybee
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,820,634.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,820,634.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,820,634.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.8 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
Robert Nelsen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
Kristina Burow
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
Steven Gillis
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,247,162.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,247,162.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,247,162.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
13.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
55083R203
1
Names of Reporting Persons
Paul Berns
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,426,528.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,426,528.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,426,528.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Lyell Immunopharma, Inc.
(b)
Address of issuer's principal executive offices:
201 Haskins Way, South San Francisco, CA 94080
Item 2.
(a)
Name of person filing:
ARCH Venture Fund IX, L.P. ("AVF IX"); ARCH Venture Partners IX, L.P. ("AVP IX LP"); ARCH Venture Partners IX, LLC ("AVP IX LLC"); ARCH Venture Fund IX Overage, L.P. ("AVF IX Overage"); ARCH Venture Partners IX Overage, L.P. ("AVF IX Overage GP"); ARCH Venture Fund XIII, L.P. ("AVF XIII"); ARCH Venture Partners XIII, L.P. ("AVP XIII LP"); ARCH Venture Partners XIII, LLC ("AVP XIII LLC") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "IX Managing Directors" and individually, each a "IX Managing Director"), Steven Gillis ("Gillis") and Kristina Burow ("Burow"), along with Nelsen and Crandell, collectively the "IX Investment Committee" and individually "IX Committee Members"; and Paul Berns ("Berns"), along with Nelsen, Crandell, Gillis, and Burow, collectively the "XIII Investment Committee" and individually "XIII Committee Members". The Reporting Entities, IX Managing Directors, IX Committee Members, and XIII Committee Members collectively are referred to as the "Reporting Persons". The Reporting Persons are filing this report with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Lyell Immunopharma, Inc. (the "Issuer").
(b)
Address or principal business office or, if none, residence:
8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631
(c)
Citizenship:
Each of AVF IX, AVF IX LP, AVF IX Overage, AVF IX Overage GP, AVF XIII and AVF XIII LP are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC and AVP XIII LLC are each a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.
(d)
Title of class of securities:
Common Stock par value $0.0001 per share
(e)
CUSIP No.:
55083R203
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
AVF IX is the record owner of 910,317 shares of Common Stock (the "AVF IX Shares") as of March 31, 2026. AVP IX LP, as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Shares.
AVF IX Overage is the record owner of 910,317 shares of Common Stock (the "AVF IX Overage Shares") as of March 31, 2026. AVF IX Overage GP, as the sole general partner of AVF IX Overage, may be deemed to beneficially own the AVF IX Overage Shares, combined with AVF IX Shares (the "IX Record Shares").
AVF XIII is the record owner of 1,426,528 shares of Common Stock (the "XIII Record Shares") as of March 31, 2026. AVP XIII LP, as the sole general partner of AVF XIII, may be deemed to beneficially own the XIII Record Shares.
AVP IX LLC, as the sole general partner of AVP IX LP and AVF IX Overage GP, may be deemed to beneficially own the IX Record Shares. As managing directors and investment committee members of AVP IX LLC, each IX Managing Director and IX Committee Members may also be deemed to share the power to direct the disposition and vote of the IX Record Shares.
AVP XIII LLC, as the sole general partner of AVP XIII LP, may be deemed to beneficially own the XIII Record Shares. As investment committee members of AVP XIII LLC, XIII Committee Members may also be deemed to share the power to direct the disposition and vote of the XIII Record Shares.
The information required by Item 4(b) is incorporated by reference to Row 11 of the cover pages hereto. The percentages set forth on the cover sheet for each Reporting Person is based upon 23,334,087 shares of Common Stock outstanding as of May 1, 2026, as reported on the Issuer's Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on May 6, 2026.
Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.
(b)
Percent of class:
See row 11 of the cover pages.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See row 5 of the cover pages.
(ii) Shared power to vote or to direct the vote:
See row 6 of the cover pages.
(iii) Sole power to dispose or to direct the disposition of:
See row 7 of the cover pages.
(iv) Shared power to dispose or to direct the disposition of:
See row 8 of the cover pages.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
ARCH Venture Fund IX, L.P.
Signature:
/s/ ARCH Venture Partners IX, L.P.
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
ARCH Venture Partners IX, LLC
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
ARCH Venture Fund IX Overage, L.P.
Signature:
/s/ ARCH Venture Partners IX Overage, L.P.
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ ARCH Venture Partners IX, LLC
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
ARCH Venture Fund XIII, L.P.
Signature:
/s/ ARCH Venture Partners XIII, L.P.
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ ARCH Venture Partners XII, LLC
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
ARCH Venture Partners IX, L.P.
Signature:
/s/ ARCH Venture Partners IX, LLC
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
ARCH Venture Partners IX Overage, L.P.
Signature:
/s/ ARCH Venture Partners IX, LLC
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
ARCH Venture Partners IX, LLC
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
ARCH Venture Partners XIII, L.P.
Signature:
/s/ ARCH Venture Partners XIII, LLC
Name/Title:
its General Partner
Date:
05/15/2026
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
ARCH Venture Partners XIII, LLC
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:
05/15/2026
Keith Crandell
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Keith Crandell
Date:
05/15/2026
Clinton Bybee
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Clinton Bybee
Date:
05/15/2026
Robert Nelsen
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for mark McDonnell
Date:
05/15/2026
Kristina Burow
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Kristina Burrow
Date:
05/15/2026
Steven Gillis
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Steven Gillis
Date:
05/15/2026
Paul Berns
Signature:
/s/ Mark McDonnell
Name/Title:
Mark McDonnell as Attorney-in-Fact for Paul Berns
Date:
05/15/2026
Comments accompanying signature: * This Schedule 13G was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Gossamer Bio, Inc. by the Reporting Persons filed with the Securities Exchange Commission on February 7, 2019 and incorporated herein in its entirety by reference.
What stake does ARCH report in LYEL via this Schedule 13G/A?
ARCH-related entities report shared voting and dispositive power over 3,247,162 shares, shown as 13.9% of the class. That percentage uses 23,334,087 shares outstanding as of May 1, 2026, per the issuer's Form 10-Q.
Which ARCH entities and individuals are named as reporting persons for LYEL?
The filing names AVF IX, AVF IX Overage, AVF XIII, AVP IX LP/LLC, AVP XIII LP/LLC and individuals including Keith Crandell, Robert Nelsen, Clinton Bybee, Kristina Burow, Steven Gillis, Paul Berns as Reporting Persons.
How many Lyell shares are shown as record-owned by AVF IX and AVF XIII?
AVF IX is reported as record owner of 910,317 shares as of March 31, 2026, while AVF XIII is reported as record owner of 1,426,528 shares, each referenced in the Item 4 ownership discussion.
Does the filing state who actually receives cash or transfers of shares?
The filing describes record ownership and shared voting/dispositive power but does not specify any cash flows or transfers. It notes percentages are calculated from the issuer's 23,334,087 shares outstanding as of May 1, 2026.
